Latest Headlines

Latest Headlines

Shire CEO: We're prepared to wait for the right deal

The way Shire CEO Flemming Ornskov sees it, smart dealmaking could set Shire on track to join its Big Biotech peers and build out its portfolio in rare diseases. But even though a little M&A could go a long way in helping the company achieve its aspirations, Shire isn't going to settle for whatever comes its way.

Playing catch-up on Big Biotech goal, Shire broadens M&A focus

Shire's $54 billion tie-up with AbbVie--and the subsequent cancellation of that deal--shook up employees and stalled CEO Flemming Ornskov's plans to transform the company into a biotech the likes of giants Gilead, Biogen and Celgene. It also took the Dublin drugmaker off course in one of its other endeavors: dealmaking.

Adults are now the prime market for ADHD drugs in U.S.

Drugmakers often do pediatric studies of their drugs to broaden the markets. But in the case of drugs for attention deficit and hyperactivity disorder (ADHD) that were primarily developed with children in mind, the market is developing the other way, with more adults now taking the drugs than children.

Shire's Vyvanse could bag another lucrative new market in menopausal women

Shire has been working hard to expand blockbuster Vyvanse beyond ADHD. And now, new research has suggested another avenue for doing just that.

The latest Shire buyout rumor: An $18.9B bid for Actelion

Acquisitive drugmaker Shire made a £12.4 billion ($18.9 billion) overture for Switzerland's Actelion, according to The Sunday Times, an offer that reportedly failed to entice the biotech's board.

Could an $18.9B Shire bid convince Actelion to ditch its independence?

Deal-hungry Shire hasn't snagged any new marketed drugs since bagging NPS Pharma in a deal it announced in January. But the rumor mill is churning again, and word has it it's set its sights on Actelion.

Shire's bid to block Lialda copies hits another snag

Shire shares slumped Thursday after a U.S. Appeals Court denied its latest attempt to fend off generic versions of its ulcerative colitis treatment Lialda. The drug is one of Shire's top sellers--and the case is one of the first reviewed under a U.S. Supreme Court patent-law ruling.

Hedge fund aims algorithms at pharma patents to sink stocks

Hedge fund manager Kyle Bass has outlined how he picks pharma patents to challenge for his new money-spinning project. The project is underpinned by two emerging assets commonly thought of as a potential boon for drug developers: large data sets and algorithms with which to interrogate them.

Pfizer could buy GSK, but would Shire or Perrigo offer better targets?

The speculation is building this week that Pfizer will either attempt another megadeal with GlaxoSmithKline or another run on AstraZeneca. Either would cut Pfizer's tax rate and give it some products to salve its various ills, lackluster stock price and poor performing portfolio. But the new thinking, like in the last 24 hours, is that smaller deals, perhaps a buyout of Shire or even Perrigo, or both, are better bets.

Shire's binge-eating push on Vyvanse feeds Q1 earnings beat

When Vyvanse in February won the FDA's first-ever approval for binge eating disorder (BED), Shire predicted the indication could help the med rake in an extra $200 million to $300 million. Shire is already making its way there, it said Thursday, and the new sales helped the company notch a Q1 profit beat.